NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Forecast, Price & News $11.11 -0.03 (-0.27%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$10.99▼$11.2450-Day Range$10.72▼$12.1952-Week Range$7.34▼$13.84Volume1.37 million shsAverage Volume2.39 million shsMarket Capitalization$3.14 billionP/E RatioN/ADividend YieldN/APrice Target$15.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside36.8% Upside$15.20 Price TargetShort InterestBearish7.53% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.17Based on 11 Articles This WeekInsider TradingSelling Shares$664,876 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.48) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector642nd out of 1,010 stocksPharmaceutical Preparations Industry322nd out of 494 stocks 3.3 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.20, Amicus Therapeutics has a forecasted upside of 36.8% from its current price of $11.11.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.53% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 1.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 1.8 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Amicus Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $664,876.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amicus Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.48) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -15.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -15.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 30.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amicus Therapeutics (NASDAQ:FOLD) StockAmicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.Read More Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Stock News HeadlinesMay 26, 2023 | americanbankingnews.comQ3 2024 EPS Estimates for Amicus Therapeutics, Inc. Reduced by Zacks Research (NASDAQ:FOLD)May 26, 2023 | seekingalpha.comFOLD Amicus Therapeutics, Inc.May 29, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 22, 2023 | seekingalpha.comAmicus Therapeutics: Finally The FDA Inspection Is Done, Time To Be PositiveMay 21, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.20 Consensus Price Target from AnalystsMay 20, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Chairman Sells $67,571.92 in StockMay 19, 2023 | americanbankingnews.comAmicus Therapeutics Target of Unusually High Options Trading (NASDAQ:FOLD)May 16, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2023 Earnings of ($0.13) Per Share, SVB Leerink ForecastsMay 29, 2023 | Stocks To Trade (Ad)Free A.I. Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 13, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Forecasted to Post Q2 2024 Earnings of ($0.02) Per ShareMay 10, 2023 | markets.businessinsider.comBerenberg Bank Keeps Their Hold Rating on Amicus (FOLD)May 10, 2023 | seekingalpha.comAmicus Therapeutics (FOLD) Q1 2023 Earnings Call TranscriptMay 10, 2023 | finance.yahoo.comAmicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate UpdatesMay 9, 2023 | msn.comAmicus Therapeutics Q1 2023 Earnings PreviewMay 6, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Chairman John F. Crowley Sells 6,044 SharesMay 4, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell Sells 11,700 Shares of StockMay 2, 2023 | finance.yahoo.comAmicus Therapeutics to Present at the Bank of America 2023 Health Care ConferenceMay 1, 2023 | finance.yahoo.comWill Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should KnowMay 1, 2023 | finance.yahoo.comAmicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023April 28, 2023 | msn.comAmicus' Opfolda combo for Pompe disease on track for EU approval after EMA nodApril 27, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Amicus (FOLD)April 27, 2023 | finanznachrichten.deAmicus Therapeutics, Inc.: Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda (miglustat) for Late-Onset Pompe DiseaseApril 26, 2023 | finance.yahoo.comAmicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe DiseaseApril 26, 2023 | finance.yahoo.comAmicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe DiseaseApril 26, 2023 | marketwatch.com8-K: AMICUS THERAPEUTICS, INC.April 26, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.20 Average PT from BrokeragesApril 24, 2023 | americanbankingnews.comCritical Contrast: Amicus Therapeutics (NASDAQ:FOLD) & Q BioMed (OTCMKTS:QBIO)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Company Calendar Last Earnings3/01/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees496Year Founded2002Price Target and Rating Average Stock Price Forecast$15.20 High Stock Price Forecast$17.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+36.8%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-236,570,000.00 Net Margins-60.63% Pretax Margin-63.47% Return on Equity-153.68% Return on Assets-27.37% Debt Debt-to-Equity Ratio3.83 Current Ratio2.89 Quick Ratio2.69 Sales & Book Value Annual Sales$329.23 million Price / Sales9.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book30.86Miscellaneous Outstanding Shares282,710,000Free Float276,778,000Market Cap$3.14 billion OptionableOptionable Beta0.81 Social Links Key ExecutivesBradley Lewis CampbellPresident, Chief Executive Officer & DirectorPat O’SullivanChief Technical Operations OfficerDaphne E. QuimiChief Financial OfficerJill WeimerChief Science OfficerMitchell GoldmanChief Medical OfficerKey CompetitorsImmunoGenNASDAQ:IMGNAlkermesNASDAQ:ALKSIronwood PharmaceuticalsNASDAQ:IRWDGeronNASDAQ:GERNMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 6,787 shares on 5/26/2023Ownership: 0.018%Ameriprise Financial Inc.Bought 122,904 shares on 5/22/2023Ownership: 0.162%JPMorgan Chase & Co.Bought 186,117 shares on 5/18/2023Ownership: 4.858%Thrivent Financial for LutheransBought 71,516 shares on 5/17/2023Ownership: 0.025%AQR Capital Management LLCBought 3,480 shares on 5/16/2023Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions FOLD Stock - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price forecast for 2023? 5 Wall Street analysts have issued 1-year price targets for Amicus Therapeutics' stock. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they anticipate the company's stock price to reach $15.20 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2023? Amicus Therapeutics' stock was trading at $12.21 at the start of the year. Since then, FOLD shares have decreased by 9.0% and is now trading at $11.11. View the best growth stocks for 2023 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.06. The biopharmaceutical company earned $88.20 million during the quarter, compared to the consensus estimate of $86.95 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 153.68% and a negative net margin of 60.63%. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), Invesco DWA Healthcare Momentum ETF (PTH), WisdomTree BioRevolution Fund (WDNA), iShares U.S. Pharmaceuticals ETF (IHE), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC). What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.78%), Avoro Capital Advisors LLC (9.66%), BlackRock Inc. (6.98%), JPMorgan Chase & Co. (4.86%), State Street Corp (3.94%) and Palo Alto Investors LP (3.72%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $11.11. How much money does Amicus Therapeutics make? Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.14 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. How many employees does Amicus Therapeutics have? The company employs 496 workers across the globe. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001. This page (NASDAQ:FOLD) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.